Research Project
Grant-in-Aid for Scientific Research (C)
Epstein-Barr virus (EBV) nuclear antigen (EBNA) 1 is expressed in every EBV-infected cell, regardless of the state of EBV infection. Although EBNA1 is thought to be a promising antigen (Ag) for immunotherapy of all EBV-associated malignancies, it is less clear whether EBNA1-specific CD4^+ T cells can act as direct effectors. Here, we investigated the ability of CD4^+ T cell clones induced with overlapping peptides covering the C-terminal region of EBNA1, and identified minimal epitopes and their restricted MHC class II molecules. Of these, a novel epitope was found to be is presented by DRB1^*0401, 0403, and 0406. Five CD4^+ T cell clones recognized endogenously processed and presented antigens on EBV-transformed lymphoblastoid cell lines and one example proved capable of killing EBV-carrying NK and T cell lines derived from patients with chronic active EBV infection. Identification of minimal epitopes facilitates design of peptide-based vaccines and our data suggest that EBNA1-specific CD4^+ T cells may play roles as direct effectors for immunotherapy targeting EBV-carrying NK and T cell malignancies.
All 2007 2006 2005
All Journal Article (21 results)
J Gen Virol. 88(Pt 3)
Pages: 770-780
Int J Cancer. 120(3)
Pages: 594-604
J Gen.Virol. 88(Pt 3)
Pages: 770-80
Int J Cancer. 120
Eur J Immunol. 36(3)
Pages: 593-602
J Virol. 80(2)
Pages: 883-890
Br J Haematol. 135(3)
Pages: 413-414
Br J Haematol. 134(4)
Pages: 406-416
Eur.J.Immunol 36(3)
J Virol 80(2)
Br J Haematol 135(3)
Br J Haematol 134(4)
Pages: 883-90
Eur J Immunol. (2006 Feb 14;[Epub ahead of print])
J.Infect.Dis. 191(4)
Pages: 531-539
Gene Ther. 12(3)
Pages: 252-258
Blood. 106(2)
Pages: 470-476
J Infect Dis. 191(4)